Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.

Histone acetylation is a post-translational modification of histones that is catalyzed by histone acetyltransferases (HATs) and plays an essential role in cellular processes. The HAT domain of EP300/CBP has recently emerged as a potential drug target for cancer therapy. Here, we describe the identification of the novel, highly potent, and selective EP300/CBP HAT inhibitor DS-9300. Our optimization efforts using a structure-based drug design approach based on the cocrystal structures of the EP300 HAT domain in complex with compounds 2 and 3 led to the identification of compounds possessing low-nanomolar EP300 HAT inhibitory potency and the ability to inhibit cellular acetylation of histone H3K27. Optimization of the pharmacokinetic properties in this series resulted in compounds with excellent oral systemic exposure, and once-daily oral administration of 16 (DS-9300) demonstrated potent antitumor effects in a castrated VCaP xenograft mouse model without significant body weight loss.

Structural Optimization of Ghrelin Receptor Inverse Agonists to Improve Lipophilicity and Avoid Mechanism-Based CYP3A4 Inactivation.

Structural optimization of 2-aminonicotinamide derivatives as ghrelin receptor inverse agonists is reported. So as to avoid mechanism-based inactivation (MBI) of CYP3A4, 1,3-benzodioxol ring of the lead compound was modified. Improvement of the main activity and lipophilicity was achieved simultaneously, leading to compound 18a, which showed high lipophilic ligand efficiency (LLE) and low MBI activity.

Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.

A series of 2-alkylamino nicotinamide analogs was prepared as orally active ghrelin receptor (ghrelinR) inverse agonists. Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight. Brain-permeable compound 33 and compound 24 with low brain permeability were tested in rat models of obesity; 30 mg/kg of compound 33 suppressed weight gain. PK/PD analysis revealed that the anti-obesity effect of ghrelinR inverse agonists depends on their brain concentrations.

2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.

New inverse agonists of the ghrelin receptor (ghrelinR) were obtained through high-throughput screening and subsequent structural modification of 2-aminoalkyl nicotinamide derivatives. The key structural feature to improve in vitro activity was the introduction of a diazabicyclo ring at the 5-position of the pyridine ring. The final product showed potent inverse agonist activity and, despite its low brain permeability, reduced food intake in both normal and obese mice. These results implied that peripheral ghrelinR activity is important for appetite control and that a peripheral ghrelinR inverse agonist could be an anti-obesity drug with reduced risk of central nervous system (CNS)-related side effects.

Platinum(II)-catalyzed intermolecular [3 + 2] cycloaddition of propadienyl silyl ethers and alkenyl ethers.

A Pt(II)-catalyzed [3 + 2] cycloaddition reaction of silyl propadienyl ethers and alkenyl ethers has been developed as the first example of the utilization of allenes as a three-carbon unit in a transition-metal-catalyzed intermolecular cycloaddition reaction. Pt(II)-containing 1,3-dipole equivalents generated by electrophilic activation of silyl propadienyl ethers using a Pt(II) catalyst reacted with various electron-rich alkenes to give synthetically useful functionalized cyclopentene derivatives in high yield with wide generality.

Generation and reaction of tungsten-containing carbonyl ylides: [3 + 2]-cycloaddition reaction with electron-rich alkenes.

Novel tungsten-containing carbonyl ylides 7, generated by the reaction of the o-alkynylphenyl carbonyl derivatives 1 with a catalytic amount of W(CO)(5)(thf), reacted with alkenes to give polycyclic compounds 5 through [3 + 2]-cycloaddition reaction followed by intramolecular C-H insertion of the produced nonstabilized carbene complex intermediates 8. In the presence of triethylsilane, these tungsten-containing carbene intermediates 8 were smoothly trapped intermolecularly by triethylsilane to give silicon-containing cycloadducts 17 with regeneration of the W(CO)(5) species. By this procedure, the scope of alkenes employable for this reaction was clarified. The presence of the tungsten-containing carbonyl ylide 7c was confirmed by direct observation of the mixture of o-ethynylphenyl ketone 1c and W(CO)(5)(thf-d(8)). Careful analysis of the intermediate by 2D NMR, along with the observation of the direct coupling with tungsten-183 employing the (13)C-labeled substrate, confirmed the structure of the ylide 7c. Examination using (E)- or (Z)- vinyl ether revealed that the [3 + 2]-cycloaddition reaction proceeded in a concerted manner and that the facial selectivity of the reaction differed considerably depending on the presence or absence of triethylsilane. These results clarified the reversible nature of this [3 + 2]-cycloaddition reaction.

Platinum(II)-catalyzed reaction of 2-alkynylbenzoates or benzothioates with vinyl ethers: a concise method for synthesis of 1-acyl-4-alkoxy- or 1-acyl-4-alkylsulfanylnaphthalene derivatives.

[reaction: see text] A concise method for the preparation of 1-acyl-4-alkoxy- or 1-acyl-4-alkylsulfanylnaphthalenes has been developed by the reaction of o-ethynylbenzoates or benzothioates with vinyl ethers, in the presence of a catalytic amount of PtCl(2). It is proposed that the reaction proceeds through [3 + 2]-cycloaddition of the platinum-containing carbonyl ylides followed by 1,2-alkyl migration.